Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Chapuis

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Cytometry. Part B, Clinical Cytometry|October 29, 2014
Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategyStéphanie Mathis, Nicolas Chapuis, Jessica Borgeot, et al.
Cytometry. Part B, Clinical Cytometry|November 18, 2014
Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategyStéphanie Mathis, Nicolas Chapuis, Jessica Borgeot, et al.
Haematologica|March 16, 2023
Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometryValentin Clichet, Delphine Lebon, Nicolas Chapuis, et al.
Leukemia & Lymphoma|August 18, 2021
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemiaJérémie Zerbit, Jerome Tamburini, Lauriane Goldwirt, et al.
Haematologica|December 3, 2009
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemiaSophie Park, Nicolas Chapuis, Jérôme Tamburini, et al.
Leukemia & Lymphoma|August 23, 2008
Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapyChadi Al-Nawakil, Jerome Tamburini, Valerie Bardet, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2015
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parametersZahra Ajgal, Nicolas Chapuis, George Emile, et al.
British Journal of Haematology|August 19, 2011
Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostimChadi Al-Nawakil, Sophie Park, Nicolas Chapuis, et al.
Blood|September 20, 2007
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathwaysJerome Tamburini, Nicolas Chapuis, Valérie Bardet, et al.
Haematologica|December 22, 2018
T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterizationMaya Belhadj, Dalila Mansour, Sophie Kaltenbach, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Cytometry. Part B, Clinical Cytometry|October 29, 2014
Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategyStéphanie Mathis, Nicolas Chapuis, Jessica Borgeot, et al.
Cytometry. Part B, Clinical Cytometry|November 18, 2014
Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategyStéphanie Mathis, Nicolas Chapuis, Jessica Borgeot, et al.
Haematologica|March 16, 2023
Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometryValentin Clichet, Delphine Lebon, Nicolas Chapuis, et al.
Leukemia & Lymphoma|August 18, 2021
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemiaJérémie Zerbit, Jerome Tamburini, Lauriane Goldwirt, et al.
Haematologica|December 3, 2009
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemiaSophie Park, Nicolas Chapuis, Jérôme Tamburini, et al.
Leukemia & Lymphoma|August 23, 2008
Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapyChadi Al-Nawakil, Jerome Tamburini, Valerie Bardet, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2015
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parametersZahra Ajgal, Nicolas Chapuis, George Emile, et al.
British Journal of Haematology|August 19, 2011
Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostimChadi Al-Nawakil, Sophie Park, Nicolas Chapuis, et al.
Blood|September 20, 2007
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathwaysJerome Tamburini, Nicolas Chapuis, Valérie Bardet, et al.
Haematologica|December 22, 2018
T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterizationMaya Belhadj, Dalila Mansour, Sophie Kaltenbach, et al.
Pageof 10